Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Bms 284756
2. Bms-284756
3. Bms284756
1. 194804-75-6
2. Ganefloxacin
3. T-3811
4. T 3811
5. Bms284756
6. (r)-1-cyclopropyl-8-(difluoromethoxy)-7-(1-methylisoindolin-5-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
7. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2,3-dihydro-1h-isoindol-5-yl]-4-oxoquinoline-3-carboxylic Acid
8. V72h9867wb
9. Bms-284756
10. Garenfloxacin
11. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methyl-2,3-dihydro-1h-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
12. 194804-75-6 Pound Not223652-90-2
13. Ncgc00181770-01
14. Garenoxacin [inn:ban]
15. Bms 284756 (*mesylate Salt*)
16. Garenoxacine
17. Garenoxacino
18. Garenoxacinum
19. Unii-v72h9867wb
20. T-3811mea
21. Bms-284756 (*mesylate Salt*)
22. Garenoxacin [mi]
23. Garenoxacin [inn]
24. Garenoxacin [mart.]
25. Garenoxacin [who-dd]
26. Chembl215303
27. Schembl2103727
28. Amy8881
29. Dtxsid30173135
30. Chebi:131716
31. Bcpp000224
32. Bcp01415
33. Ex-a3040
34. Zinc3585048
35. Bdbm50481219
36. S5908
37. Akos015920281
38. Bcp9000709
39. Cs-4989
40. Db06160
41. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid
42. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-1-methylisoindolin-5-yl]-4-oxo-quinoline-3-carboxylic Acid
43. 1-cyclopropyl-8-(difluoromethoxy)-7-[(1r)-2,3-dihydro-1-methyl-1h-isoindol-5-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
44. Hy-17460
45. A16856
46. 804g756
47. J-012614
48. J-521409
49. Q3758306
50. (r)-1-cyclopropyl-8-difluoromethoxy-7-(1-methyl-2, 3-dihydro-1h-5-isoindolyl)-4-oxo-1, 4-dihydro-3-quinolinecarboxylic Acid
51. (r)-1-cyclopropyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinoline-carboxylic Acid
52. (r)-1-cyclopropyl-8-difluoromethoxy-7-(1-methyl-2,3-dihydro-1h-5-isoindolyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid
| Molecular Weight | 426.4 g/mol |
|---|---|
| Molecular Formula | C23H20F2N2O4 |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | 426.13911345 g/mol |
| Monoisotopic Mass | 426.13911345 g/mol |
| Topological Polar Surface Area | 78.9 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 771 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in bacterial infection.
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA19 - Garenoxacin
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
Global Sales Information
ABOUT THIS PAGE
A Garenoxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Garenoxacin, including repackagers and relabelers. The FDA regulates Garenoxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Garenoxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Garenoxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Garenoxacin supplier is an individual or a company that provides Garenoxacin active pharmaceutical ingredient (API) or Garenoxacin finished formulations upon request. The Garenoxacin suppliers may include Garenoxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Garenoxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Garenoxacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Garenoxacin active pharmaceutical ingredient (API) in detail. Different forms of Garenoxacin DMFs exist exist since differing nations have different regulations, such as Garenoxacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Garenoxacin DMF submitted to regulatory agencies in the US is known as a USDMF. Garenoxacin USDMF includes data on Garenoxacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Garenoxacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Garenoxacin suppliers with USDMF on PharmaCompass.
Garenoxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Garenoxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Garenoxacin GMP manufacturer or Garenoxacin GMP API supplier for your needs.
A Garenoxacin CoA (Certificate of Analysis) is a formal document that attests to Garenoxacin's compliance with Garenoxacin specifications and serves as a tool for batch-level quality control.
Garenoxacin CoA mostly includes findings from lab analyses of a specific batch. For each Garenoxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Garenoxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Garenoxacin EP), Garenoxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Garenoxacin USP).
LOOKING FOR A SUPPLIER?
